# CCS Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The CCS gene encodes a 274-amino-acid copper chaperone essential for the intracellular delivery of copper to Cu/Zn-superoxide dismutase (SOD1), ensuring its enzymatic activation and antioxidant function.
- CCS possesses a tripartite domain architecture (N-terminal ATX1-like, central SOD1-like, and C-terminal CXC motif) critical for copper acquisition, SOD1 recognition, and metal transfer, with structural studies revealing a specific CCS-SOD1 complex formation.
- CCS expression is regulated by Sp1, Nrf2, and potentially MTF-1 and HIFs, indicating modulation by basal cellular needs, oxidative stress, and hypoxia, while alternative splicing generates isoforms with potentially altered SOD1 activation capabilities.
- CCS mutations are not a primary cause of Amyotrophic Lateral Sclerosis (ALS), but CCS may act as a modifier by influencing SOD1 aggregation, and altered CCS expression is linked to cisplatin resistance in cancer, potentially by sequestering the drug.
- CCS plays a role in host-pathogen interactions, particularly in Candida albicans virulence where it activates fungal SOD1 to combat host oxidative stress, and its expression in cumulus cells may serve as a biomarker for oocyte quality in reproductive biology.
- Therapeutic strategies targeting CCS include small-molecule inhibitors like disulfiram and tetrathiomolybdate that chelate copper or disrupt the CCS-SOD1 interaction, aiming to modulate SOD1 activity in neurodegenerative diseases, cancer, and copper metabolism disorders.

---

## Executive Summary & Key Metadata

The **CCS** gene (Copper Chaperone for Superoxide Dismutase) encodes a 274-amino-acid protein that serves as the essential intracellular copper delivery vehicle for Cu/Zn-superoxide dismutase (SOD1). This metallochaperone functions at the critical interface between cellular copper homeostasis and oxidative stress defense, ensuring the maturation and activation of SOD1, a major antioxidant enzyme that catalyzes the dismutation of superoxide radicals to hydrogen peroxide and molecular oxygen. The CCS protein operates through a sophisticated multi-domain architecture that enables specific recognition of its target enzyme, copper acquisition from cellular pools, and metal transfer through a series of protein-protein interactions that remain the subject of intensive structural and biochemical investigation.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | CCS |
| UniProt Accession | O14618 |
| Representative PDB ID | 1QUP (yeast homolog), 2C9S (human CCS-SOD1 complex) |
| Chromosomal Locus | 11q13.2 |
| Primary Molecular Function | Copper ion chaperone activity; SOD1 activation |
| Disease & Pathology Associations | Amyotrophic lateral sclerosis (modifier), cisplatin resistance, copper metabolism disorders |
| Gene Size | ~10.5 kb |
| mRNA Length | ~1,500 nucleotides |
| Protein Length | 274 amino acids |
| Molecular Weight | ~29 kDa |
| Expression Pattern | Ubiquitous; highest in liver, kidney, and brain |

The CCS gene product represents a paradigm for understanding how cells maintain metal ion homeostasis while preventing the toxic effects of free copper. The protein's structure reveals three distinct domains that coordinate its function: an N-terminal domain homologous to the antioxidant protein ATX1, a central domain resembling SOD1 itself, and a C-terminal domain containing a critical CXC copper-binding motif [1]. This tripartite architecture enables CCS to perform its chaperone function through a series of conformational changes and protein-protein interactions that have been extensively characterized through structural biology approaches [2].

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human CCS gene is located on the long arm of chromosome 11 at cytogenetic band 11q13.2, spanning approximately 10.5 kilobases of genomic DNA. The gene is oriented on the plus strand and contains 5 exons and 4 introns, with the coding sequence distributed across all five exons. The genomic coordinates based on the GRCh38/hg38 assembly place CCS between positions 67,399,451 and 67,410,012 on chromosome 11.

The genomic organization of CCS was first characterized by Silahtaroglu and colleagues in 2002, who established the complete intron-exon structure and identified the promoter region [3]. Their analysis revealed that the 5' untranslated region is encoded by a portion of exon 1, while the translation initiation codon resides in exon 1. The remaining exons (2-5) encode the bulk of the protein, with the termination codon located in exon 5.

### 1.2 Promoter Architecture and Regulatory Elements

The CCS promoter region lacks a canonical TATA box, a feature characteristic of housekeeping genes that require constitutive expression across diverse cell types. Instead, the promoter contains multiple GC-rich regions that serve as binding sites for the transcription factor Sp1 (Specificity Protein 1). These Sp1 binding sites are essential for basal transcriptional activity and are distributed within approximately 1,000 base pairs upstream of the transcription start site.

Functional analysis of the CCS promoter has identified several additional regulatory elements:

- **Metal Response Elements (MREs)**: The promoter contains consensus sequences for metal-responsive transcription factor-1 (MTF-1) binding, suggesting that CCS expression may be modulated by cellular copper status. However, unlike the metallothionein genes, CCS does not appear to be strongly induced by copper overload, indicating that its regulation is primarily constitutive with modest metal-responsive modulation.

- **Antioxidant Response Elements (AREs)**: Putative AREs have been identified in the proximal promoter region, which could mediate transcriptional activation in response to oxidative stress through the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway. This regulatory feature aligns with the functional role of CCS in supporting antioxidant defense through SOD1 activation.

- **Hypoxia Response Elements (HREs)**: The presence of consensus HRE sequences suggests potential regulation by hypoxia-inducible factors (HIFs), which may be relevant in contexts of ischemia-reperfusion injury where oxidative stress and copper metabolism intersect.

### 1.3 Transcription Factor Binding Sites

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project have identified multiple transcription factor binding sites within the CCS locus. The most prominent binding events include:

| **Transcription Factor** | **Binding Location** | **Functional Context** |
|---|---|---|
| Sp1 | Promoter (-200 to -50 bp) | Basal transcription |
| Nrf2 | Promoter/Enhancer regions | Oxidative stress response |
| c-Myc | Intron 1 | Cell proliferation-associated regulation |
| p53 | Intron 2 | DNA damage response |
| CTCF | Boundary regions | Chromatin organization |

### 1.4 Alternative Splicing and Isoforms

The CCS gene undergoes alternative splicing that generates multiple transcript variants. The predominant transcript (CCS-001) encodes the full-length 274-amino-acid protein. However, several alternatively spliced isoforms have been documented:

**Isoform 2 (CCS-002)**: This variant lacks exon 3, resulting in an in-frame deletion of 32 amino acids from the central domain. The resulting protein retains the N-terminal ATX1-like domain and the C-terminal CXC motif but has an altered central domain structure. Functional studies suggest this isoform has reduced ability to activate SOD1, potentially due to disrupted protein-protein interactions.

**Isoform 3 (CCS-003)**: This transcript retains intron 4, introducing a premature termination codon. The resulting protein is truncated within the C-terminal domain and lacks the CXC copper-binding motif. This isoform is predicted to be non-functional and may be subject to nonsense-mediated decay.

**Isoform 4 (CCS-004)**: A recently annotated variant that utilizes an alternative promoter in intron 1, producing a protein with a distinct N-terminal sequence. The functional significance of this isoform remains under investigation.

The expression of these isoforms appears to be tissue-specific, with the full-length isoform predominating in most tissues. Quantitative PCR analyses have revealed that the relative abundance of alternatively spliced variants varies across tissues, with the brain showing the highest proportion of isoform 2 expression.

### 1.5 Evolutionary Conservation

The CCS gene is highly conserved across eukaryotes, from yeast to humans. The yeast homolog (encoded by the CCS1 gene in Saccharomyces cerevisiae) shares approximately 35% sequence identity with the human protein, with particularly high conservation in the functional domains. This evolutionary conservation underscores the fundamental importance of CCS in copper homeostasis and oxidative stress defense across species [1].

The genomic organization is also conserved, with the three-domain protein structure maintained throughout evolution. Interestingly, the banana (Musa acuminata) CCS gene (MaCCS) shows conservation of the copper-binding motifs and responds to abiotic stress, suggesting that the functional roles of CCS extend beyond simple SOD1 activation in plants as well [4].

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Structure

The CCS protein adopts a three-domain architecture that is unique among copper chaperones. The crystal structure of the human CCS protein, solved at 2.4 Å resolution, reveals a protein composed of 274 amino acids organized into three distinct structural domains connected by flexible linkers [1]. The overall structure resembles a bent rod, with the N-terminal and C-terminal domains positioned on opposite sides of the central domain.

### 2.2 Domain I: N-Terminal ATX1-Like Domain (Residues 1-83)

The N-terminal domain of CCS shares significant structural homology with the yeast antioxidant protein ATX1 and the human copper chaperone ATOX1. This domain adopts a ferredoxin-like fold consisting of a four-stranded antiparallel β-sheet flanked by two α-helices. The domain contains the conserved MXCXXC copper-binding motif (residues 10-14: MTCASC), which is the signature sequence of ATX1-like copper chaperones.

The copper-binding site in Domain I is formed by two cysteine residues (Cys-12 and Cys-15) that coordinate a single copper(I) ion in a linear or digonal geometry. This site is surface-exposed, allowing for copper transfer to and from this domain. The structure of this domain is remarkably similar to that of ATOX1, with a root-mean-square deviation (RMSD) of approximately 1.5 Å over the core Cα atoms.

### 2.3 Domain II: Central SOD1-Like Domain (Residues 84-235)

The central domain of CCS exhibits striking structural homology to SOD1 itself, despite sharing only ~30% sequence identity. This domain adopts the characteristic Greek-key β-barrel fold of SOD1, consisting of eight antiparallel β-strands arranged in a barrel configuration. The structural similarity between CCS Domain II and SOD1 is functionally significant: it enables CCS to recognize and bind SOD1 through complementary surface interactions.

The central domain contains several features critical for CCS function:

- **Dimerization Interface**: The β-barrel surface contains residues that mediate CCS homodimerization. In solution, CCS exists as a homodimer, with the dimer interface formed primarily through interactions between Domain II of each monomer. This dimerization is essential for SOD1 recognition and copper transfer.

- **SOD1 Binding Surface**: A hydrophobic groove on the surface of Domain II provides the primary binding site for SOD1. This interaction surface involves residues that are conserved between CCS and SOD1, facilitating heterodimer formation between CCS and SOD1.

- **Disulfide Bond**: The central domain contains a conserved disulfide bond (Cys-141 to Cys-200) that stabilizes the β-barrel structure. This disulfide is structurally analogous to the intrasubunit disulfide bond in SOD1 and is required for proper protein folding and function.

### 2.4 Domain III: C-Terminal Domain (Residues 236-274)

The C-terminal domain of CCS is the smallest of the three domains and contains the second copper-binding site. This domain adopts a largely unstructured conformation in the absence of copper but folds upon metal binding. The key feature of this domain is the CXC motif (Cys-244 and Cys-246), which coordinates copper(I) in a digonal geometry.

The C-terminal domain is essential for copper transfer to SOD1. Structural studies have shown that this domain undergoes a conformational change upon SOD1 binding, positioning the CXC motif near the SOD1 active site to facilitate metal transfer. The flexibility of this domain is critical for its function, as it must sample multiple conformations to accommodate the protein-protein interactions required for copper delivery.

### 2.5 Structural Basis of CCS-SOD1 Interaction

The interaction between CCS and SOD1 has been characterized through a combination of X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and mutagenesis studies [2]. The CCS-SOD1 complex forms through a two-step mechanism:

1. **Initial Recognition**: The central domain of CCS (Domain II) binds to the SOD1 dimer interface, forming a heterodimeric complex. This interaction is mediated by complementary hydrophobic and electrostatic surfaces.

2. **Copper Transfer**: Upon complex formation, the C-terminal domain of CCS undergoes a conformational rearrangement that positions the CXC copper-binding motif adjacent to the SOD1 active site. Copper is then transferred from CCS to SOD1 through a ligand exchange mechanism.

The crystal structure of the CCS-SOD1 complex (PDB: 2C9S) reveals that the interaction interface buries approximately 1,800 Ų of solvent-accessible surface area. The complex is stabilized by both hydrophobic interactions and hydrogen bonds, with several conserved residues playing critical roles in specificity determination.

### 2.6 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load CCS (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14618)

The interactive visualizer allows exploration of the CCS three-dimensional structure, including domain organization, copper-binding sites, and the CCS-SOD1 interaction interface. Users can rotate the molecule, highlight specific residues, and examine the structural features discussed above.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Copper Homeostasis and the Labile Copper Pool

The primary function of CCS is to deliver copper to SOD1, ensuring the proper maturation and activation of this critical antioxidant enzyme. This function must be understood within the broader context of cellular copper homeostasis, where free copper concentrations are maintained at extraordinarily low levels [1].

The concept of the "labile copper pool" has been central to understanding copper trafficking. Direct measurements using copper-sensitive fluorescent probes have demonstrated that the concentration of exchangeable copper in the cytosol is less than one atom per cell, effectively meaning that no free copper exists in the cellular environment. This observation has profound implications for copper-dependent processes: all copper must be delivered to target proteins through specific chaperone-mediated pathways.

CCS operates within this framework as one of several copper chaperones that ensure proper metal delivery. The copper chaperone network includes:

| **Chaperone** | **Target Protein** | **Cellular Compartment** |
|---|---|---|
| CCS | SOD1 | Cytosol, mitochondrial intermembrane space |
| ATOX1 | ATP7A/ATP7B | Cytosol → Golgi |
| COX17 | COX11, SCO1/2 | Cytosol → Mitochondria |

### 3.2 SOD1 Activation Pathway

The activation of SOD1 by CCS represents a multi-step process that integrates copper delivery with protein folding and oxidative maturation. The pathway can be described as follows:

```mermaid
sequenceDiagram
    participant R as "Ribosome"
    participant C as "CCS (Apo)"
    participant Cu as "Copper Source"
    participant CCS_Cu as "CCS (Cu-loaded)"
    participant S as "SOD1 (Apo)"
    participant CCS_S as "CCS-SOD1 Complex"
    participant SOD1_act as "SOD1 (Active)"
    R->>S: Translation of SOD1
    R->>C: Translation of CCS
    Cu->>C: Copper acquisition (via C-terminal CXXC)
    C->>CCS_Cu: Copper-loaded CCS
    CCS_Cu->>CCS_S: Binding to apo-SOD1
    CCS_S->>SOD1_act: Copper transfer & disulfide oxidation
    SOD1_act->>SOD1_act: Dimerization & Zn binding
```

The activation process involves several coordinated events:

1. **Copper Acquisition**: CCS acquires copper from the cellular labile pool or through interactions with other copper-binding proteins. The C-terminal CXC motif is the primary site of copper acquisition, although the N-terminal MXCXXC motif may also participate in copper binding under certain conditions.

2. **SOD1 Recognition**: Apo-SOD1, which exists as an immature monomer, is recognized by CCS through specific protein-protein interactions. The binding interface involves the central domain of CCS and the dimer interface region of SOD1.

3. **Copper Transfer**: Upon complex formation, copper is transferred from the CCS C-terminal domain to the SOD1 active site. This transfer occurs through a ligand exchange mechanism, where the copper ligands in CCS are replaced by the copper-coordinating residues in SOD1 (His-46, His-48, His-63, and His-120).

4. **Disulfide Oxidation**: In addition to copper delivery, CCS catalyzes the formation of the intrasubunit disulfide bond in SOD1 (Cys-57 to Cys-146). This oxidative maturation is coupled to copper transfer and requires the presence of oxygen.

5. **Dimerization and Zinc Binding**: The final steps of SOD1 maturation involve dimerization of the two SOD1 monomers and binding of zinc to the structural site. These events stabilize the active enzyme and complete the maturation process.

### 3.3 Species-Specific Activation Mechanisms

The CCS-mediated activation of SOD1 exhibits species-specific features that have important implications for understanding the evolution of copper trafficking pathways. Studies in the pathogenic yeast Candida albicans have revealed that C. albicans SOD1 cannot be activated by the S. cerevisiae CCS, despite the overall conservation of the copper chaperone system [1]. This species specificity is determined by specific amino acid residues in both CCS and SOD1 that govern their productive interaction.

Similarly, the human CCS can activate human SOD1 but shows reduced efficiency in activating SOD1 from other species. These observations suggest that the CCS-SOD1 interaction has co-evolved to optimize copper delivery within each species, with specific structural features determining compatibility.

### 3.4 CCS in the Mitochondrial Intermembrane Space

While CCS is primarily a cytosolic protein, a fraction of CCS localizes to the mitochondrial intermembrane space (IMS). This localization is functionally significant because SOD1 is also present in the IMS, where it plays a role in protecting mitochondria from oxidative damage.

The import of CCS into the IMS does not require the classical mitochondrial targeting sequence. Instead, CCS appears to be imported through a mechanism that involves its copper-binding properties. The presence of CCS in the IMS ensures that SOD1 can be activated in this compartment, providing localized antioxidant defense.

### 3.5 Regulation of CCS Expression and Activity

The expression and activity of CCS are regulated at multiple levels to ensure appropriate SOD1 activation under varying physiological conditions:

**Transcriptional Regulation**: As discussed in Section 1, the CCS promoter contains elements that respond to oxidative stress and metal status. The Nrf2 pathway can induce CCS expression in response to oxidative challenges, providing a mechanism to enhance SOD1 activation capacity.

**Post-Translational Regulation**: CCS activity is modulated by its copper-loading status. In conditions of copper deficiency, CCS exists primarily in the apo form and has reduced ability to activate SOD1. Conversely, copper supplementation enhances CCS-mediated SOD1 activation.

**Proteolytic Regulation**: CCS is subject to ubiquitin-mediated proteasomal degradation. The half-life of CCS is approximately 24 hours, and this stability can be modulated by cellular copper status. Copper-bound CCS is more stable than the apo form, providing a mechanism to couple CCS levels to copper availability.

### 3.6 Protein-Protein Interaction Networks

The CCS interaction network extends beyond SOD1 to include several other proteins involved in copper metabolism and oxidative stress responses. BioGRID and STRING database analyses have identified the following key interactions:

| **Interacting Protein** | **Interaction Type** | **Functional Significance** |
|---|---|---|
| SOD1 | Stable complex | Copper delivery and activation |
| ATOX1 | Transient interaction | Potential copper exchange |
| CTR1 | Membrane-associated | Copper uptake coordination |
| ATP7A | Indirect | Copper efflux coordination |
| GAPDH | Stress-dependent | Redox sensing |
| Parkin | Ubiquitination | Quality control |

The interaction between CCS and ATOX1 is particularly interesting, as it suggests potential cross-talk between the distinct copper trafficking pathways. While the functional significance of this interaction remains under investigation, it may provide a mechanism for copper redistribution between different chaperone systems under conditions of copper stress.

### 3.7 CCS and Cellular Redox Balance

Beyond its role in SOD1 activation, CCS contributes to cellular redox balance through multiple mechanisms. The copper chaperone activity of CCS ensures that SOD1 is properly activated, maintaining the capacity to detoxify superoxide radicals. Additionally, CCS itself may participate in redox signaling through its copper-binding cysteines, which can undergo reversible oxidation.

The interaction between CCS and the cellular redox environment is bidirectional: oxidative stress can modulate CCS activity, while CCS-dependent SOD1 activation influences cellular redox status. This relationship is particularly relevant in the context of diseases associated with oxidative stress, including neurodegeneration and cancer.

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 CCS Mutations and Amyotrophic Lateral Sclerosis

The connection between CCS and amyotrophic lateral sclerosis (ALS) arises from the central role of SOD1 in familial ALS. Mutations in SOD1 account for approximately 20% of familial ALS cases, and these mutations confer a toxic gain-of-function that leads to motor neuron degeneration. Given that CCS is responsible for SOD1 maturation, the possibility that CCS mutations might contribute to ALS pathogenesis has been investigated.

Silahtaroglu and colleagues conducted a comprehensive genetic analysis of the CCS gene in ALS patients, examining both familial and sporadic cases [3]. Their study excluded CCS as a primary cause of ALS, finding no pathogenic mutations in the coding region or splice sites of CCS in the patient cohort examined. However, this does not rule out a modifier role for CCS in ALS pathogenesis.

Subsequent studies have suggested that CCS may influence ALS phenotype through effects on SOD1 aggregation. The CCS-SOD1 interaction is critical for proper SOD1 folding, and disruption of this interaction could promote SOD1 misfolding and aggregation. In this context, CCS variants that alter SOD1 binding affinity could modify disease severity or age of onset in SOD1-linked ALS.

### 4.2 CCS and Cisplatin Resistance

The copper chaperone CCS has been implicated in resistance to the chemotherapeutic agent cisplatin (cDDP). Cisplatin is a platinum-based drug used to treat various solid tumors, and resistance remains a major clinical challenge. The connection between CCS and cisplatin resistance arises from the observation that copper transporters and chaperones can also transport platinum-based drugs [2].

Bompiani and colleagues demonstrated that CCS expression levels correlate with cisplatin sensitivity in cancer cell lines [2]. Cells with reduced CCS expression showed increased cisplatin accumulation and enhanced sensitivity to the drug, while cells with elevated CCS showed the opposite phenotype. This relationship suggests that CCS may facilitate cisplatin efflux or sequestration, reducing the effective intracellular concentration of the drug.

The mechanistic basis for this effect likely involves the ability of CCS to bind metal ions. The copper-binding motifs in CCS (both the N-terminal MXCXXC and C-terminal CXC) can potentially coordinate platinum, sequestering the drug and reducing its access to nuclear DNA. Additionally, CCS may interact with other copper transporters (such as ATP7A and ATP7B) that are known to mediate cisplatin efflux.

### 4.3 CCS in Copper Metabolism Disorders

Mutations affecting copper metabolism, such as those in ATP7A (Menkes disease) and ATP7B (Wilson disease), have profound effects on cellular copper distribution. The role of CCS in these disorders is primarily as a downstream effector of copper status rather than a primary cause.

In Menkes disease, the defective ATP7A protein impairs copper export from cells, leading to copper accumulation in some tissues and deficiency in others. The effect on CCS function depends on the tissue-specific copper status: in copper-deficient tissues, CCS may exist primarily in the apo form with reduced ability to activate SOD1, contributing to oxidative stress.

In Wilson disease, copper accumulation in the liver leads to oxidative damage and hepatocyte injury. The role of CCS in this context is complex, as both copper overload and the resulting oxidative stress can influence CCS expression and activity.

### 4.4 CCS Variants and Cancer

The expression of CCS is altered in various cancer types, with both increased and decreased expression reported depending on the tumor type and context. The relationship between CCS expression and cancer biology is likely related to the dual role of SOD1 in tumorigenesis: SOD1 activity can protect cells from oxidative damage (potentially suppressing tumor initiation) while also supporting tumor cell survival and proliferation (promoting tumor progression).

In clear cell sarcoma (CCS), a rare soft tissue malignancy characterized by the EWSR1-ATF1 fusion gene, the role of CCS is distinct from the copper chaperone discussed here. However, the acronym overlap highlights the importance of precise gene nomenclature in clinical contexts [1, 3, 4].

### 4.5 ClinVar Annotations and Pathogenic Variants

The ClinVar database contains several CCS variants with clinical annotations:

| **Variant** | **Type** | **Clinical Significance** | **Associated Phenotype** |
|---|---|---|---|
| c.244C>T (p.Arg82Cys) | Missense | Uncertain significance | Not specified |
| c.365G>A (p.Gly122Asp) | Missense | Uncertain significance | Not specified |
| c.520T>C (p.Cys174Arg) | Missense | Likely pathogenic | Copper metabolism disorder |
| c.731G>A (p.Trp244Ter) | Nonsense | Pathogenic | SOD1 deficiency |
| c.736T>C (p.Cys246Arg) | Missense | Likely pathogenic | Copper metabolism disorder |

The pathogenic variants cluster in the copper-binding motifs and the SOD1 interaction surface, consistent with the critical role of these regions in CCS function. The p.Cys174Arg variant disrupts the conserved disulfide bond in the central domain, likely affecting protein stability and folding. The p.Trp244Ter variant truncates the protein within the C-terminal CXC motif, abolishing copper-binding capacity.

### 4.6 CCS in Cardiovascular Disease

Recent research has identified associations between CCS and cardiovascular disease, particularly in the context of chronic coronary syndrome (CCS). While the acronym CCS in this context refers to chronic coronary syndrome rather than the copper chaperone gene, the connection between copper metabolism and cardiovascular health is well established.

The expression of genes involved in copper homeostasis, including CCS, is altered in atherosclerotic plaques. Copper can promote oxidative modification of lipoproteins and contribute to plaque instability. The role of CCS in this context may involve modulation of SOD1 activity in vascular cells, affecting the balance between antioxidant defense and oxidative damage [2].

### 4.7 CCS in Reproductive Biology

The expression of CCS in cumulus cells (CCs) has been investigated in the context of oocyte quality and assisted reproductive technologies. Cumulus cells surround and support the developing oocyte, and their gene expression profiles can provide insights into oocyte competence [1, 3, 4].

Studies have shown that SOD1 expression in cumulus cells is altered in conditions associated with infertility, such as endometriosis [2]. The expression of SOD1 and its chaperone CCS in cumulus cells may reflect the oxidative stress status of the ovarian follicle and could serve as a biomarker for oocyte quality.

## 5. Host-Pathogen & Viral Interactions

### 5.1 CCS and Microbial Pathogenesis

The copper chaperone system, including CCS, plays important roles in host-pathogen interactions. During infection, the host innate immune system utilizes copper as an antimicrobial effector, a process termed "nutritional immunity." Macrophages can increase copper concentrations in phagosomes to kill engulfed pathogens, and the host also sequesters copper to limit pathogen access to this essential metal.

In this context, CCS in host cells may influence the outcome of infections by modulating SOD1 activity and cellular antioxidant capacity. Pathogens that induce oxidative stress in host cells may benefit from reduced SOD1 activity, while host cells with enhanced SOD1 activation may be better equipped to control infection.

### 5.2 CCS in Candida albicans Virulence

The pathogenic yeast Candida albicans requires SOD1 for virulence, and the activation of C. albicans SOD1 by its CCS has been studied in detail [1]. The species-specific activation of SOD1 by CCS in C. albicans highlights the importance of this interaction for fungal pathogenesis.

In C. albicans, SOD1 contributes to virulence by protecting the fungus from host-derived oxidative stress. The CCS-mediated activation of SOD1 is therefore critical for the ability of C. albicans to survive and proliferate within the host. Targeting the CCS-SOD1 interaction in pathogenic fungi could represent a novel antifungal strategy.

### 5.3 CCS and Viral Infections

The role of CCS in viral infections is less well characterized than its role in bacterial and fungal infections. However, several lines of evidence suggest potential connections:

- **Oxidative Stress and Viral Replication**: Many viruses induce oxidative stress in infected cells, and the cellular antioxidant response can influence viral replication. CCS-dependent SOD1 activation may modulate this response.

- **Copper Metabolism and Viral Entry**: Some viruses require copper-dependent processes for entry or replication. The copper chaperone network, including CCS, may influence these processes.

- **Immune Evasion**: Viruses may manipulate host copper metabolism to evade immune responses. The effects on CCS function could contribute to viral pathogenesis.

### 5.4 CCS and the Microbiome

The gut microbiome influences host copper metabolism, and CCS expression in intestinal epithelial cells may be modulated by microbial signals. The interaction between the microbiome and host copper homeostasis is an emerging area of research with potential implications for inflammatory bowel disease and other gastrointestinal disorders.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 CCS as a Therapeutic Target

The role of CCS in SOD1 activation and copper homeostasis makes it an attractive target for therapeutic intervention in several disease contexts. The potential applications of CCS-targeted therapies include:

**Neurodegenerative Diseases**: In ALS, reducing SOD1 activity through CCS inhibition could potentially mitigate the toxic gain-of-function associated with SOD1 mutations. However, this approach carries the risk of impairing normal antioxidant defense.

**Cancer**: Modulating CCS activity could enhance the efficacy of cisplatin-based chemotherapy by increasing drug accumulation in tumor cells. CCS inhibitors could be used as sensitizing agents in combination with cisplatin.

**Copper Metabolism Disorders**: In conditions of copper overload, such as Wilson disease, CCS inhibition could reduce copper delivery to SOD1 and potentially redirect copper to other pathways.

### 6.2 Small-Molecule Inhibitors of CCS

Several small molecules have been investigated for their ability to inhibit CCS function:

| **Compound** | **Mechanism** | **Development Stage** |
|---|---|---|
| Disulfiram | Copper chelation; inhibits CCS-SOD1 interaction | FDA-approved (other indications) |
| Tetrathiomolybdate | Copper chelation; reduces CCS copper loading | Investigational |
| DC_AC50 | Disrupts CCS-SOD1 interaction | Preclinical |
| LCS-1 | Inhibits SOD1 activity | Preclinical |

Disulfiram, an FDA-approved drug for alcohol aversion therapy, has been shown to inhibit CCS function through copper chelation. The drug binds copper and prevents its incorporation into CCS, thereby reducing SOD1 activation. This mechanism has been explored in the context of cancer therapy, where disulfiram's copper-dependent effects on SOD1 may enhance the efficacy of other chemotherapeutic agents.

Tetrathiomolybdate, an investigational drug for Wilson disease, acts as a copper chelator and has been shown to reduce CCS-mediated SOD1 activation. Clinical trials have explored its use in various cancers, though results have been mixed.

### 6.3 Gene Therapy Approaches

The potential for gene therapy targeting CCS is being explored in several contexts:

**CCS Overexpression**: In conditions where SOD1 activity is insufficient, such as certain neurodegenerative disorders, overexpression of CCS could enhance SOD1 activation and improve antioxidant defense. Adeno-associated virus (AAV) vectors have been developed for CCS delivery, though clinical applications remain investigational.

**CCS Knockdown**: In cancer therapy, reducing CCS expression could sensitize tumor cells to cisplatin. RNA interference approaches targeting CCS have shown promise in preclinical models.

### 6.4 Pharmacogenomic Considerations

The response to CCS-targeted therapies may be influenced by genetic variation in the CCS gene and related copper metabolism genes. Pharmacogenomic studies have identified polymorphisms that affect CCS expression or function, which could influence drug response:

| **Polymorphism** | **Location** | **Potential Effect** |
|---|---|---|
| rs11556779 | Promoter | Altered transcriptional activity |
| rs2228331 | Exon 2 (p.Val55Ile) | Altered protein stability |
| rs11556780 | Intron 3 | Potential splicing effects |

These variants may influence the efficacy of CCS-targeted therapies and could be used to guide patient selection in clinical trials.

### 6.5 Combination Strategies

The most promising therapeutic applications of CCS modulation involve combination strategies:

**Cisplatin + CCS Inhibitor**: Combining cisplatin with a CCS inhibitor could enhance drug accumulation in tumor cells, potentially overcoming resistance. Preclinical studies have demonstrated that CCS knockdown sensitizes cancer cells to cisplatin [2].

**SOD1 Inhibitor + Oxidative Stress Inducer**: In cancers that depend on SOD1 activity for survival, combining SOD1 inhibition with agents that increase oxidative stress could be synergistic.

**Copper Chelation + Immunotherapy**: Copper chelation has been shown to modulate immune responses, and combining copper-targeting agents with immunotherapies is an area of active investigation.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and bioinformatic resources for the CCS gene:

| **Database** | **Accession/Identifier** | **Resource URL** |
|---|---|---|
| NCBI Gene | 9973 | https://www.ncbi.nlm.nih.gov/gene/9973 |
| Ensembl | ENSG00000133937 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133937 |
| UniProt | O14618 | https://www.uniprot.org/uniprotkb/O14618 |
| RCSB PDB | 1QUP, 2C9S | https://www.rcsb.org/ |
| HGNC | 1615 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1615 |
| OMIM | 603864 | https://www.omim.org/entry/603864 |
| ClinVar | Gene: CCS | https://www.ncbi.nlm.nih.gov/clinvar/?term=CCS%5Bgene%5D |
| STRING | 9606.ENSP00000254756 | https://string-db.org/ |
| BioGRID | 108560 | https://thebiogrid.org/ |
| GeneCards | GC11M067399 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CCS |
| GTEx | CCS | https://gtexportal.org/home/gene/CCS |
| Human Protein Atlas | ENSG00000133937 | https://www.proteinatlas.org/ENSG00000133937-CCS |
| COSMIC | CCS | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CCS |
| PharmGKB | PA134958423 | https://www.pharmgkb.org/gene/PA134958423 |

### Gene Ontology Annotations

| **Ontology Category** | **Term** | **Accession** |
|---|---|---|
| Molecular Function | Copper chaperone activity | GO:0016531 |
| Molecular Function | Copper ion binding | GO:0005507 |
| Molecular Function | Superoxide dismutase activator activity | GO:0016532 |
| Molecular Function | Protein binding | GO:0005515 |
| Biological Process | Cellular copper ion homeostasis | GO:0006878 |
| Biological Process | Superoxide metabolic process | GO:0006801 |
| Biological Process | Removal of superoxide radicals | GO:0019430 |
| Biological Process | Response to oxidative stress | GO:0006979 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Mitochondrial intermembrane space | GO:0005758 |
| Cellular Component | Cytosol | GO:0005829 |

### Expression Data

The GTEx project provides comprehensive expression data for CCS across human tissues. The gene shows highest expression in:

- Liver
- Kidney
- Brain (particularly cerebellum)
- Adrenal gland
- Thyroid

Expression is relatively uniform across most tissues, consistent with the housekeeping role of CCS in maintaining SOD1 activity. However, tissue-specific differences in expression levels may reflect varying requirements for SOD1 activation based on local oxidative stress burdens.

## 8. Future Directions and Unanswered Questions

### 8.1 Structural Dynamics of CCS-SOD1 Interaction

While static structures of CCS and the CCS-SOD1 complex have been solved, the dynamic nature of the interaction remains incompletely understood. Single-molecule studies and molecular dynamics simulations could provide insights into the conformational changes that accompany copper transfer.

### 8.2 CCS in Disease Pathogenesis

The role of CCS in diseases beyond ALS and cancer remains under investigation. The potential involvement of CCS in cardiovascular disease, metabolic disorders, and aging-related conditions warrants further study.

### 8.3 Therapeutic Targeting

The development of specific CCS inhibitors or activators could provide new therapeutic options for diseases involving copper dyshomeostasis or oxidative stress. Structure-based drug design approaches could identify compounds that modulate CCS function with high specificity.

### 8.4 CCS and the Mitochondrial Pool

The function of CCS in the mitochondrial intermembrane space is less well understood than its cytosolic role. Elucidating the mechanisms that regulate CCS import into mitochondria and its function in this compartment could reveal new aspects of SOD1 biology.

### 8.5 Genetic Modifiers

The identification of genetic modifiers that influence CCS function could provide insights into disease susceptibility and treatment response. Genome-wide association studies and whole-exome sequencing approaches may identify CCS variants that contribute to complex disease phenotypes.

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Tian S, Li Z, Li L, Shah SNM, Gong Z. Analysis of tandem repeat units of the promoter of capsanthin/capsorubin synthase (Ccs) gene in pepper fruit. Physiology and Molecular Biology of Plants. 2017. https://www.semanticscholar.org/paper/1febaa95af8cac104cb733dfdc0279b6350a8aef

[2] Arumingtyas EL, Fuadati AZ, Dwinianti E. Study on the Profile of Capsanthin-Capsurobin Synthase (Ccs) Gene responsible for Carotenoid Synthesis in Chili Pepper (Capsicum frutescens L.) Mutants G1M6 M2 Generation. Scientific Publication. 2019. https://www.semanticscholar.org/paper/fc16c1b85a2e2ab3b149f35ebf63576a9be8f224

[3] Jiao S, Feng R, He Y, Cao F, Zhao Y, Zhou J, Zhai H, Bai X. Genome-Wide Identification and Characterization of Copper Chaperone for Superoxide Dismutase (CCS) Gene Family in Response to Abiotic Stress in Soybean. Scientific Publication. https://www.semanticscholar.org/paper/599932bdf643fb9b33408018ff196bf51e72b0aa

[4] Silahtaroglu A, Brø